[HTML][HTML] Sialic acid and Siglec receptors in tumor immunity and immunotherapy

NR Mantuano, H Läubli - Seminars in Immunology, 2024 - Elsevier
Immunotherapy, including immune checkpoint inhibition, has transformed cancer therapy in
recent years, providing new and potentially curative options for patients with even advanced …

Glycoengineering in antigen-specific immunotherapies

Y Li, H Chen, J Gao, P Wu, S Hong - Current Opinion in Chemical Biology, 2024 - Elsevier
Advances in immunotherapy have revolutionized modern medical care paradigms.
However, many patients respond poorly to the current FDA-approved treatment regimens …

The tissue glycome as regulator of immune activation and tolerance mediated by C-type lectins and Siglecs

E Nardini, E Rodriguez, Y van Kooyk - Seminars in Immunology, 2024 - Elsevier
The immune system is a complex network of highly specialized microenvironments,
denominated niches, which arise from dynamic interactions between immune and …

A nanobody-enzyme fusion protein targeting PD-L1 and sialic acid exerts anti-tumor effects by C-type lectin pathway-mediated tumor associated macrophages …

Y Tong, R Chen, X Lu, C Chen, G Sun, X Yu… - International Journal of …, 2025 - Elsevier
Aberrant sialylated glycosylation in the tumor microenvironment is a novel immune
suppression pathway, which has garnered significant attention as a targetable glycoimmune …

A Unified Atlas of T cell Glycophysiology

FN Izzati, H Choksi, P Giuliana, D Abd-Rabbo… - BioRxiv, 2024 - biorxiv.org
Glycans are emerging as important regulators of T cell function but remain poorly
characterized across the functionally distinct populations that exist in vivo. Here, we couple …

[HTML][HTML] Mechanistic and Therapeutic Implications of Protein and Lipid Sialylation in Human Diseases

X Zhong, AM D'Antona, JC Rouse - International Journal of Molecular …, 2024 - mdpi.com
Glycan structures of glycoproteins and glycolipids on the surface glycocalyx and luminal
sugar layers of intracellular membrane compartments in human cells constitute a key …

[HTML][HTML] Resha** the tumor microenvironment by degrading glycoimmune checkpoints Siglec-7 and-9

C Wang, Y Hou, J Zak, Q Zheng, KA McCord, M Wu… - …, 2024 - pmc.ncbi.nlm.nih.gov
Cancer treatment has been rapidly transformed by the development of immune checkpoint
inhibitors targeting CTLA-4 and PD-1/PD-L1. However, many patients fail to respond …